{
    "Rank": 570,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00416650",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "VCC THO 0214"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P50CA090949",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P50CA090949"
                        },
                        {
                            "SecondaryId": "P30CA068485",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA068485"
                        },
                        {
                            "SecondaryId": "VU-VCC-THO-0214"
                        },
                        {
                            "SecondaryId": "VU-VCC-IRB-02-0168"
                        },
                        {
                            "SecondaryId": "GENENTECH-VU-VCC-THO-0214"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Vanderbilt-Ingram Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer",
                "OfficialTitle": "Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer."
            },
            "StatusModule": {
                "StatusVerifiedDate": "March 2013",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "July 2002"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "October 2007",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "March 2013",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "December 27, 2006",
                "StudyFirstSubmitQCDate": "December 27, 2006",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "December 28, 2006",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "April 2, 2013",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "April 4, 2013",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "William Pao, MD",
                    "ResponsiblePartyInvestigatorTitle": "Professor of Medicine, Cancer Biology, & Pathology/ Microbiology/ Immunology; Director, Division of Hematology and Oncology; Ingram Professor of Cancer Research; Director, Personalized Cancer Medicine; Medical Oncologist",
                    "ResponsiblePartyInvestigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Vanderbilt-Ingram Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\n\nPURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nDetermine the major objective response rate (partial response and complete response) in patients with advanced bronchoalveolar cell non-small cell lung cancer treated with erlotinib hydrochloride.\n\nSecondary\n\nAssess the quality of life of patients treated with this regimen.\nDetermine the duration of response and time to disease progression in patients treated with this regimen.\nDetermine the median survival of patients treated with this regimen.\n\nOUTLINE: This is an open-label, nonrandomized, multicenter study.\n\nPatients receive oral erlotinib hydrochloride daily in the absence of disease progression or unacceptable toxicity."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IIIB non-small cell lung cancer",
                        "stage IV non-small cell lung cancer",
                        "bronchoalveolar cell lung cancer",
                        "recurrent non-small cell lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "16",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Therapeutic Intervention",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: erlotinib hydrochloride"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "erlotinib hydrochloride",
                            "InterventionDescription": "All patients will receive 150 mg orally daily",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Therapeutic Intervention"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Tarceva, OSI-774"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Major objective response rate (complete response and partial response)",
                            "PrimaryOutcomeDescription": "Per Response Evaluation in Solid Tumors (RECIST) criteria v. 1.1: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions",
                            "PrimaryOutcomeTimeFrame": "At 4 weeks and then every 8 weeks"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Worst grade toxicity",
                            "SecondaryOutcomeDescription": "Number of patients with worst-grade toxicity at each of five grades (1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, disabling, 5 = death) following NCI Common Toxicity Criteria, v. 2. Drug is discontinued for disease progression, unacceptable toxicity, patient undergoes radiation or other chemotherapy, or withdraws from study",
                            "SecondaryOutcomeTimeFrame": "weekly for 4 weeks, then every 8 weeks to discontinuation of drug"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Quality of life as measured by the Lung Cancer Symptom Scale for patients",
                            "SecondaryOutcomeDescription": "The Lung Cancer Symptom Scale for patients is a nine-item scale with 0 = lowest rating (least) to 100 = highest rating (worst) for the measurement of symptom burden for loss of appetite, fatigue, cough, dyspnea, hemoptysis, activity, quality of life, lung cancer symptoms, and pain.",
                            "SecondaryOutcomeTimeFrame": "baseline, every week for 5 weeks, and then every 4 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Survival",
                            "SecondaryOutcomeDescription": "Duration of time from date of study entry to death from any cause or to the last date the patient is known to be alive.",
                            "SecondaryOutcomeTimeFrame": "from study entry to date of death or last date known alive"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed bronchoalveolar cell (or a variant) non-small cell lung cancer (NSCLC)\n\nStage IIIB (malignant pleural or pericardial effusion) disease\nStage IV disease\nRecurrent and/or medically inoperable disease\nMeasurable or evaluable indicator lesions\nNo uncontrolled CNS metastases (i.e., any known CNS lesion that is radiographically unstable, symptomatic, and/or requiring escalating doses of corticosteroids)\n\nPATIENT CHARACTERISTICS:\n\nECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%\nLife expectancy \u2265 8 weeks\nWBC \u2265 3,000/mm\u00b3\nHemoglobin \u2265 9.0 g/dL\nPlatelet count \u2265 100,000/mm\u00b3\nBilirubin \u2264 1.0 mg/dL\nAST \u2264 2 times upper limit of normal\nCreatinine \u2264 1.5 mg/dL OR creatinine clearance \u2265 55 mL/min\nNot pregnant or nursing\nFertile patients must use effective contraception\n\nNo significant medical history or unstable medical condition, including any of the following:\n\nUnstable systemic disease\nCongestive heart failure\nRecent myocardial infarction\nUnstable angina\nActive infection\nUncontrolled hypertension\nNo other active malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal cell or squamous cell skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nSee Disease Characteristics\nAt least 3 weeks since prior radiation therapy to a major bone marrow-containing area\nAt least 3 weeks since prior chemotherapy\nNo more than 1 prior chemotherapy regimen for NSCLC\nNo prior systemic cytotoxic chemotherapy for other malignant diseases\nNo prior erlotinib hydrochloride or other agents targeting the HER family (e.g., cetuximab, trastuzumab [Herceptin\u00ae], or gefitinib)\nNo concurrent radiotherapy or chemotherapy",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "William Pao, MD",
                            "OverallOfficialAffiliation": "Vanderbilt-Ingram Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Northwestern Memorial Hospital",
                            "LocationCity": "Chicago",
                            "LocationState": "Illinois",
                            "LocationZip": "60611",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Memorial Sloan-Kettering Cancer Center",
                            "LocationCity": "New York",
                            "LocationState": "New York",
                            "LocationZip": "10021",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Vanderbilt-Ingram Cancer Center",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37232",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "MD Anderson Cancer Center",
                            "LocationCity": "Houston",
                            "LocationState": "Texas",
                            "LocationZip": "77030",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5229",
                            "ConditionBrowseLeafName": "Adenocarcinoma, Bronchiolo-Alveolar",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069347",
                            "InterventionMeshTerm": "Erlotinib Hydrochloride"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M398",
                            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
                            "InterventionBrowseLeafAsFound": "Stomach",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}